Ardelyx Inc (ARDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $776.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Ardelyx Inc (ARDX) Competitors
The companies most similar to Ardelyx are Adlai Nortye Ltd. American Depositary Shares (ANL), Avalo Therapeutics (AVTX) and ARS Pharmaceuticals (SPRY). By market cap, Ardelyx ranks 7th of the 13 companies on this page; Ultragenyx (RARE) is the largest at $1.64B.
Peer Comparison
ARDX's ROIC of -6.5% is above the peer median of -65.0%, and its revenue growth of 15.7% is above the median of 4.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Ardelyx (ARDX) | $776.74M | N/A | 1.6x | -11.8% | -6.5% | 15.7% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| ARS Pharmaceuticals, Inc (SPRY) | $391.06M | N/A | 2.9x | -163.6% | -143.8% | 16.0% | 0.00% |
| Syndax Pharmaceuticals Inc (SNDX) | $850.77M | N/A | 2.8x | -72.3% | -65.0% | 81.6% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Janux Therapeutics Inc (JANX) | $695.65M | N/A | 29.6x | 0.0% | N/A | -7.1% | 0.00% |
| Annexon Inc (ANNX) | $747.79M | N/A | N/A | 0.0% | -84.6% | 0.0% | 0.00% |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Verastem Inc (VSTM) | $1.03B | N/A | 7.8x | -178.4% | -110.4% | 113.6% | 0.00% |
| 4D Molecular Therapeutics Inc (FDMT) | $689.52M | N/A | 8.5x | -208.6% | -46.4% | 4506.0% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $781.25M | 95.1x | 7.9x | -35.9% | -65.0% | 4.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Ardelyx, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| ARS Pharmaceuticals, Inc (SPRY) | ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe... | SPRY competitors |
| Syndax Pharmaceuticals Inc (SNDX) | Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. | SNDX competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Janux Therapeutics Inc (JANX) | Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology... | JANX competitors |
| Annexon Inc (ANNX) | Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. | ANNX competitors |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular... | MLYS competitors |
| Verastem Inc (VSTM) | Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. | VSTM competitors |
| 4D Molecular Therapeutics Inc (FDMT) | 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. | FDMT competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
Frequently Asked Questions About ARDX
Who are Ardelyx's main competitors?
The companies most similar to Ardelyx include Adlai Nortye Ltd. American Depositary Shares (ANL), Avalo Therapeutics (AVTX), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX) and Theravance Biopharma (TBPH), listed from the closest match.
Who is Ardelyx's biggest competitor?
Ultragenyx (RARE) is the largest of the similar companies at $1.64B; Adlai Nortye Ltd. American Depositary Shares (ANL) is the closest match by business profile, size, sector and industry.
How does ARDX stock compare with its competitors?
ARDX's P/S is 1.6x against a peer median of 7.9x; its net margin is -11.8% against a peer median of -35.9%.
Which of Ardelyx's competitors pays a higher dividend?
Ardelyx pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Ardelyx bigger than its competitors?
No. Ardelyx is 7th by market cap among the 13 companies on this page; the largest is Ultragenyx (RARE) at $1.64B.
ARDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts